'Parkinson's Drug Market Will Reach $3426 Million in 2016' Predicts New Visiongain Report

LONDON, January 8, 2013 /PRNewswire/ --

A new report by visiongain predicts that the overall world market for drugs to treat Parkinson's disease will reach $3426m in 2016. That revenue forecast and others appear in Parkinson's Disease: World Drug Market 2013-2023, published in January 2013. Visiongain is a business information provider based in London, UK.

The study finds that new first-in-class drugs will boost the Parkinson's disease market. Adenosine receptor antagonists will gain approval in the near term followed by new glutamatergic drugs, with Novartis's AFQ056 (mavoglurant) and Addex's dipraglurant vying to be the first in this class. These approvals will invigorate the market and offset patent expiries for older drugs such as Boehringer Ingelheim's Mirapex.

Dr James Evans, a pharmaceutical industry analyst in visiongain, said: "Our analyses identify several new symptomatic treatments for unmet needs in Parkinson's disease (PD), including orthostatic hypotension, Parkinson's-related psychosis and sialorrhoea. However, the R&D pipeline contains more-significant candidates than these, in the form of possible disease-modifying agents that could change the treatment paradigm. These include repurposed existing drugs such as exenatide and isradapine, and new small-molecule agents such as Phytopharm's Cogane and Newron's safinamide. Many possible neuroprotectants are novel agents, including gene therapies, stem cell treatments and peptides.

"The PD market is entering a transition away from the established drugs, towards new mechanisms of action. Requip, Mirapex and Stalevo are all off-patent now. Teva's Azilect will become the leading drug, almost by default, as the last of the current market leaders to have some patent protection remaining.

"New and emerging therapies hold the promise of major changes to the current treatment paradigm. For example, the glutamatergic drugs may deal with levodopa-induced dyskinesia. That might sound like a minor tweak to the existing symptomatic treatments, but actually it's important because it would allow physicians to prescribe L-dopa earlier and more vigorously. At the moment they often hold off with L-dopa because of side-effects. Start using L-dopa earlier and you could dispense with agents like dopamine agonists as first-line treatments: L-dopa with the right adjuncts would be better. You also have reformulations of L-dopa in the R&D pipeline, such as Impax's Rytary candidate, which would help drive that change.

"The real goal is to get disease-modifying treatments approved, and that will begin to happen in the next ten years. The negative verdict on Teva's ADAGIO trials of Azilect shows that there's going to be a high burden of proof. But within the next five years or so there'll be gene therapies in phase III, products like Oxford BioMedica's ProSavin will be on the way. Someone is going to crack PD disease-modification in the next 10 years, and it will be a different market once that's happened."

The study concludes that the PD market will change significantly by 2023, with new mechanisms of action capturing market share, and new biomarkers helping to validate trials of neuroprotectant agents and prove disease modification for the first time.

Visiongain's report shows revenue forecasts to 2023 at overall world market, submarket and national level. It forecasts these world-level submarkets:

• Dopaminergic agents
• Dopamine receptor agonists
• COMT inhibitors
• MAO inhibitors
• Other mechanisms of action (grouped).

Research, data and analyses cover activities of Novartis, GlaxoSmithKline (GSK), Newron, Teva, Addex, Abbott and other pharmaceutical and biotechnology companies.

That new study discusses R&D and commercial developments, shows research interviews and predicts overall revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5) and the BRIC nations (grouped analysis).

Parkinson's Disease: World Drug Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Parkinson's Disease: World Drug Market 2013-2023 please visit http://www.visiongain.com/Report/957/Parkinson's-Disease-World-Drug-Market-2013-2023

Companies Listed
Abbott Laboratories
Acadia Pharmaceuticals
Adamas Pharmaceuticals
Addex Therapeutics
Affiris
Allon Therapeutics
Amarantus BioSciences
Amgen
Amicus Therapeutics
Amylin Pharmaceuticals
AnGes
Ark Therapeutics
AstraZeneca
Axxonis Pharma
Bayer
BIAL - Portela
Biogen Idec
Bioprojet Pharma
BioSante Pharmaceuticals
Biotie Therapies
Biovail
Boehringer Ingelheim
BrainStorm Cell Therapeutics
Buck Institute for Research on Ageing
Ceregene
Chelsea Therapeutics
Ciba-Geigy
Cipla
Civitas Therapeutics
Columbia University
Dainippon Sumitomo
Dendreon
Depomed
DiaGenic
Domain Therapeutics
Dr. Reddy's Laboratories
Dresden University of Technology
Durin Technologies
Eisai
EMD Serono
Endo Pharmaceuticals
Erba
European Medicines Agency (EMEA/EMA)
Farmitalia Carlo
Food and Drug Administration (US FDA)
Genervon Biopharmaceuticals
Genzyme
GlaxoSmithKline (GSK)
Impax Pharmaceuticals (Impax Laboratories)
Intec Pharma
Ipsen
Juvantia Pharma
Kaneka Nutrients
Kyoto University
Kyowa Hakko Kirin
Living Cell Technologies
Lundbeck
Maypro Industries
Meiji Seika
Merck & Co.
Merck KGaA
Merck Serono
Mitsubishi Gas Chemical
Mount Sinai School of Medicine
Mundipharma Research
Mylan
Napp Pharmaceuticals
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Neurological Disorders and Stroke (NINDS, US)
National Institutes of Health (NIH, US)
Neupro
Neuraltus
Neuren Pharmaceuticals
Neurim Pharmaceuticals
Neuroderm
NeuroGeneration
NeuroHealing
Neurologix
NeuroSearch
Newron
Novartis
NsGene
Orient Pharma
Orion
Oxford BioMedica
Pacific Rainbow International
Parkinson's UK
Parr
Pfizer
Pharmacia
Phytopharm
Power3 Medical Products
Roche
Roxane
Sandoz
Sanofi
Santhera
Schering Plough
Servier
ShenZhou Biology & Technology
SK Biosciences
Solvay Pharmaceuticals
Sun
Swedish Orphan Biovitrum
Synergen Corporation
Synosia Therapeutics
Technion-Israel Institute of Technology
Tel Aviv University
Teva Pharmaceutical Industries
The Michael J. Fox Foundation
Titan Pharmaceuticals
UCB
uniQure
University College London (UCL)
University of Bristol Institute of Clinical Neuroscience
University of California, Los Angeles (UCLA)
University of Kentucky
University of Nebraska
University of Rochester
Valeant
Varinel
Vectura Group
Vernalis
Vical
Watson Pharmaceuticals
Wockhardt
XenoPort
Xiamen Kingdomway Group
Zambon
Zhejiang Medicine Company 

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

For an executive summary please contact:
Email: Sara Peerun
sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100